Noncoding RNAs in drug-resistant pancreatic cancer: A review - 28/10/20
, Shiyao Lu a , Xubin Xie a , Xuyang Yi a , He Huang b, c, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 12 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | A great number of dysregulated noncoding RNAs are correlated with drug resistance of pancreatic cancer. |
• | Noncoding RNAs have an important regulatory role in the mechanism of pancreatic cancer drug resistance. |
• | Noncoding RNAs can be served as prognostic markers and novel therapeutic targets in pancreatic cancer. |
Abstract |
Pancreatic cancer is the fourth-leading cause of cancer-related deaths and is expected to be the second-leading cause of cancer-related deaths in Europe and the United States by 2030. The high fatality rate of pancreatic cancer is ascribed to untimely diagnosis, early metastasis and limited responses to both chemotherapy and radiotherapy. Although gemcitabine, 5-fluorouracil and some other drugs can profoundly improve patient prognosis, most pancreatic cancer patients eventually develop drug resistance, leading to poor clinical outcomes. The underlying mechanisms of pancreatic cancer drug resistance are complicated and inconclusive. Interestingly, accumulating evidence has demonstrated that different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), play a crucial role in pancreatic cancer resistance to chemotherapy reagents. In this paper, we systematically summarize the molecular mechanism underlying the influence of ncRNAs on the generation and development of drug resistance in pancreatic cancer and discuss the potential role of ncRNAs as prognostic markers and new therapeutic targets for pancreatic cancer.
Le texte complet de cet article est disponible en PDF.Abbreviations : ncRNA, miRNA/miR, lncRNA, circRNA, GEM, 5-FU, Dox, EMT, sncRNA, snRNA, snoRNA, piRNA, 3′-UTR, mRNA, CSCs, Bim, TAM, PDAC, OS, CAFs, PTEN, TFAP2C, GJs, CCNG2, SMARCC1, A20, KLF4, TUBB3, ABCC5, USP22, HMGB1, RRM1, DNA-PK, FGF2, FGFR1, CCND2, PDCD4, YAP1, DPD, FdUMP, TYMS, RB1, VIM, PTN, DDP, Capan-1 cells, TUG1, HCP5, ceRNA, BRD4, Linc-ROR, ROS, GAS5, SOCS3, MMP7
Keywords : Pancreatic cancer, Drug resistance, MicroRNA, Long non-coding RNA, Circular RNA
Plan
Vol 131
Article 110768- novembre 2020 Retour au numéro
Article précédent
- Cross-talk between oxidative stress signaling and microRNA regulatory systems in carcinogenesis: Focused on gastrointestinal cancers
- Abolfazl Akbari, Hassan Mehrad Majd, Reyhane Rahnama, Javad Heshmati, Mojgan Morvaridzadeh, Shahram Agah, Seyed Mohammad Amini, Mohsen Masoodi
- Therapeutic advances in Fabry disease: The future awaits
- Sam Kant, Mohamed G. Atta
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?